Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px
Document › Details

Takeda Pharmaceutical Co. Ltd.. (1/5/18). "Press Release: Takeda Announces Intention to Acquire TiGenix. Expands Takeda’s Late Stage Pipeline and Leadership in Gastroenterology". Osaka.

Organisations Organisation Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
  Organisation 2 TiGenix N.V. (Euronext + Nasdaq: TIG)
  Group Takeda (Group)
Products Product Cx601 (expanded allogenic stem cell product)
  Product 2 investment banking
Index term Index term TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share ANNOUNCED
Persons Person Plump, Andrew (Takeda 201610 CMO + CSO)
  Person 2 Bravo, Eduardo (TiGenix 201112 CEO)
     


   
Record changed: 2018-01-08

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Takeda (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 600x80px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px